Evidence map›Paper›PMID 33656759›Full record

ArticleJournal of gastroenterology and hepatology2021

Programmed cell death-ligand 1 expression in hepatocellular carcinoma and its correlation with clinicopathological characteristics.

Haibo Mou, Qiu-An Yang, Lanfang Yu, Ting Wang, Kui Liu, Rong Shen, Xuedong Pan, Yi Dai, Qing Wan, Fangling Zhou and 6 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of gastroenterology and hepatology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Review
  3. Article
  4. Article
  5. Article
  6. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

16 authors.

Haibo MouDepartment of Medical Oncology, Shulan (Hangzhou) Hospital Affiliated to Zhejiang Shuren University Shulan International Medical College, Hangzhou, Zhejiang, China.
Qiu-An YangCancer Center, Qilu Hospital of Shandong University, Jinan, Shandong, China.
Lanfang YuDepartment of Medical Oncology, Shulan (Hangzhou) Hospital Affiliated to Zhejiang Shuren University Shulan International Medical College, Hangzhou, Zhejiang, China.
Ting WangDepartment of Hepatobiliary and Pancreatic Surgery, Shulan (Hangzhou) Hospital Affiliated to Zhejiang Shuren University Shulan International Medical College, Hangzhou, Zhejiang, China.
Kui LiuDepartment of Hepatobiliary Surgery, The Affiliated Hospital of Qingdao University, Qingdao, Shandong, China.
Rong ShenDepartment of Chemotherapy, Shandong Provincial Hospital Affiliated to Shandong University, Jinan, Shandong, China.
Xuedong PanDepartment of Clinical Pathology, OrigiMed, Minhang, Shanghai, China.ORCID https://orcid.org/0000-0002-1159-9018
Yi DaiDepartment of Clinical Pathology, OrigiMed, Minhang, Shanghai, China.
Qing WanDepartment of Clinical Pathology, OrigiMed, Minhang, Shanghai, China.
Fangling ZhouDepartment of Clinical Pathology, OrigiMed, Minhang, Shanghai, China.
Lili QianDepartment of Clinical Pathology, OrigiMed, Minhang, Shanghai, China.
Donglin ChenDepartment of Clinical Pathology, OrigiMed, Minhang, Shanghai, China.
Thomas YauDepartment of Medicine, Li Ka Shing Faculty of Medicine, The University of Hong Kong, Hong Kong, China.
Xiaowei DongMedical Laboratory, OrigiMed, Jiading, Shanghai, China.
Xuemei WangDepartment of Pathology, China-Japan Union Hospital of Jilin University, Changchun, China.
Shuang WangDepartment of Pathology, Nanfang Hospital, Southern Medical University, Guangzhou, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

BACKGROUND AND

aimProgrammed cell death-ligand 1 (PD-L1) immunohistochemistry score has been approved as the predictive biomarker for anti-PD1/PD-L1 therapy in several advanced malignancies. Although its predictive role remained inconclusive in hepatocellular carcinoma, ongoing study of anti-PD1/PD-L1 therapy showed promising results. However, less is known about the PD-L1 immunohistochemistry score and factors correlated with it in hepatocellular carcinoma. We investigated PD-L1 immunohistochemistry scores in a large cohort of hepatocellular carcinoma, as well as its correlation with various clinical and genomic factors.

methodsImmunohistochemistry was performed to detect the expression of PD-L1 protein in 315 hepatocellular carcinoma tissues. All slides were independently reviewed by three senior pathologists. Next-generation YS panel (450 genes) sequencing was performed on 309 patients.

resultsHigher PD-L1 expression as measured by combined positive score (CPS) was associated with increased Edmondson-Steiner grade (grade III vs II, P = 0.041) and TP53 mutations (P = 0.021). PD-L1 CPS had no correlation with tumor mutational burden (Spearman's correlation coefficient 0.067). PD-L1 CPS was not significantly associated with hepatitis B virus infection.

conclusionsOur data indicated that patients with higher Edmondson-Steiner grade (grade III) had significantly higher PD-L1 CPS than patients with lower Edmondson-Steiner grade (grade II). Patients with TP53 mutations had significantly higher PD-L1 expression.

Indexed as

B7-H1 AntigenCarcinoma, HepatocellularLiver NeoplasmsAdolescentAdultAgedAged, 80 and overApoptosisBiomarkers, TumorFemaleHumansImmunochemistryMaleMiddle AgedMutationRetrospective StudiesB7-H1 AntigenBiomarkers, TumorE-S gradeHepatocellular carcinomaImmunohistochemistryPD-L1TP53Tumor mutational burden

Identifiers

PMID33656759
PMCPMC8518358

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.